The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115
University of Chicago Gleacher Center at the Booth School of Business
450 N Cityfront Plaza Drive
Chicago, IL 60611
Kaiser Permanente Center for Total Health
700 2nd St NE, Washington, DC 20002
ICER will host a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit will include discussion of how these methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system to allow for broader insurance coverage for innovative new treatments.
To facilitate the discussion, ICER will produce a Briefing Paper on Spinraza™ (nusinersen, Biogen), a new drug for spinal muscular atrophy (SMA) recently approved by the FDA. The paper will review the evidence on the clinical effectiveness of Spinraza and seek to understand the costs of the drug's development as a case study. It will also compare methods used by academic researchers and others to evaluate the long-term value of drugs for rare conditions, including those affecting children. The Briefing Paper will not include an ICER value-based price benchmark, nor will the meeting involve a vote on the value of these drugs. Instead, the meeting will seek broad input from all perspectives on how the methods used by ICER and other groups can best be tailored to meet the challenge of assessing the value of orphan drugs and provide an objective foundation for discussions about fair pricing, insurance coverage, and payment mechanisms.Register or Register for the Live Webcast
Location TBD (California)
The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.
Location TBD (New England)
ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.
The Midwest CEPAC will convene to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.
The California Technology Assessment Forum convened to discuss ICER's report on treatments for Multiple Sclerosis.
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.
The Midwest CEPAC convened in October 2016 to discuss ICER's report on treatments for non-small cell lung cancer.
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on obeticholic acid (Intercept Pharmaceuticals, Inc.) for use in PBC and NASH.
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in June 2016 to discuss the comparative effectiveness and value of diabetes prevention programs.
At its inaugural meeting, the Midwest CEPAC convened to discuss the comparative clinical effectiveness and value of therapies for multiple myeloma.
The New England CEPAC convened on March 31, 2016 to discuss the comparative clinical effectiveness and value of outpatient palliative care.
The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in February 2016 to discuss a drug for patients with severe eosinophilic asthma. The asthma drug, mepolizumab (Nucala®, GlaxoSmithKline), is a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5).
CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for Management of Congestive Heart Failure
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting on Thursday, October 29, 2015 to discuss the comparative effectiveness and value of two interventions for patients with congestive heart failure (CHF) – the drug Entresto (a combination of valsartan and sacubitril, Novartis AG), and the CardioMEMS HF System (St. Jude Medical). The CardioMEMS HF System is a heart failure monitor manufactured by St. Jude Medical and approved by the FDA in May, 2014. Entresto is a drug for the treatment of heart failure with reduced ejection fraction and was approved by the FDA on July 7, 2015.